NO20031409L - Ionestyrkeuavhengig farmasoytiske preparat med langvarig frigivelse - Google Patents

Ionestyrkeuavhengig farmasoytiske preparat med langvarig frigivelse

Info

Publication number: NO20031409L
Authority: NO; Norway
Prior art keywords: pharmaceutical preparations; release pharmaceutical; ion strength; strength independent; independent long
Prior art date: 2000-09-29

Application number

NO20031409A

Other languages

English (en)

Other versions

NO20031409D0 (no

Inventor

Henricus R M Gorissen

Henderik W Frijlink

Original Assignee

Solvay Pharm Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-29

Filing date

2003-03-27

Publication date

2003-03-27

2003-03-27 Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv

2003-03-27 Publication of NO20031409L publication Critical patent/NO20031409L/no

2003-03-27 Publication of NO20031409D0 publication Critical patent/NO20031409D0/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physiology (AREA)
Psychology (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Otolaryngology (AREA)

NO20031409A 2000-09-29 2003-03-27 Ionestyrkeuavhengig farmasöytiske preparat med langvarig frigivelse NO20031409D0 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP00203381		2000-09-29
NL1016295		2000-09-29
PCT/EP2001/011285 WO2002026214A1 (en)	2000-09-29	2001-09-28	Ion-strength independent sustained release pharmaceutical formulation

Publications (2)

Publication Number	Publication Date
NO20031409L true NO20031409L (no)	2003-03-27
NO20031409D0 NO20031409D0 (no)	2003-03-27

Family

ID=26072736

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20031409A NO20031409D0 (no)	2000-09-29	2003-03-27	Ionestyrkeuavhengig farmasöytiske preparat med langvarig frigivelse

Country Status (25)

Country	Link
US (1)	US8034379B2 (no)
EP (1)	EP1345595B1 (no)
JP (1)	JP5049450B2 (no)
KR (1)	KR100833469B1 (no)
CN (1)	CN1466451B (no)
AT (1)	ATE361060T1 (no)
AU (2)	AU2002223572B2 (no)
BR (1)	BR0114272A (no)
CA (1)	CA2426666A1 (no)
CZ (1)	CZ299411B6 (no)
DE (1)	DE60128263T2 (no)
DK (1)	DK1345595T3 (no)
DZ (1)	DZ3473A1 (no)
ES (1)	ES2284709T3 (no)
HU (1)	HUP0301177A3 (no)
IL (2)	IL154731A0 (no)
MX (1)	MXPA03002769A (no)
NO (1)	NO20031409D0 (no)
NZ (1)	NZ524641A (no)
PL (1)	PL203217B1 (no)
PT (1)	PT1345595E (no)
RU (1)	RU2285519C2 (no)
SI (1)	SI1345595T1 (no)
SK (1)	SK287066B6 (no)
WO (1)	WO2002026214A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070099931A1 (en) *	2004-03-19	2007-05-03	Wyeth	Pharmaceutical dosage forms and compositions
PL1750766T3 (pl)	2004-05-11	2013-12-31	Eb Ip Lybrido B V	Preparaty farmaceutyczne i ich zastosowania do leczenia zaburzeń seksualnych u kobiet
US20060003003A1 (en) *	2004-06-28	2006-01-05	Bakker Johan A	Oral sustained release formulation of tedisamil with gastric retention properties
JP2008504250A (ja) *	2004-06-28	2008-02-14	ソルベイ・フアーマシユーチカルズ・ベー・ブイ	胃貯留特性を有する経口用徐放性テジサミル製剤。
AR049936A1 (es) *	2004-06-28	2006-09-13	Solvay Pharm Bv	Formulacion oral de liberacion sostenida de tedisamil con propiedades de retencion gastrica
JP2006143598A (ja) *	2004-11-16	2006-06-08	Nichi-Iko Pharmaceutical Co Ltd	経時的な変色を抑制した医薬組成物
GT200600403A (es) *	2005-09-09	2007-09-19		Composiciones y formas de dosificacion farmaceuticas
EP1790343A1 (en)	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
US8669258B2 (en) *	2006-10-30	2014-03-11	The Board Of Regents Of The University Of Texas System	Treatment for gastroparesis using sepiapterin
US7863275B2 (en) *	2006-10-30	2011-01-04	The Board Of Regents Of The University Of Texas System	Uses of tetrahydrobiopterin and derivatives thereof
EP1925307A1 (en)	2006-11-03	2008-05-28	Emotional Brain B.V.	Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US7965077B2 (en) *	2008-05-08	2011-06-21	Everspin Technologies, Inc.	Two-axis magnetic field sensor with multiple pinning directions
HUE049501T2 (hu)	2009-02-13	2020-09-28	Romark Laboratories Lc	Nitazoxanidot tartalmazó szabályozott felszabadulású gyógyszerkészítmény
WO2013157833A1 (ko) *	2012-04-18	2013-10-24	서울대학교산학협력단	베타-차단제를 유효성분으로 포함하는 비만, 비만으로 인한 대사성 질환 및 골감소증 예방, 개선 또는 치료용 조성물
KR102116495B1 (ko) *	2013-08-28	2020-06-03	삼성디스플레이 주식회사	축합환 화합물을 포함하는 유기 전계 발광 소자
AR101476A1 (es)	2014-08-07	2016-12-21	Acerta Pharma Bv	Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
CN104352471A (zh) *	2014-11-21	2015-02-18	哈尔滨圣吉药业股份有限公司	一种马来酸氟伏沙明缓释片及其制备方法
IL271606B2 (en)	2017-06-21	2024-05-01	Minerva Neurosciences Inc	Gastro-resistant controlled release oral dosage forms
TWI841545B (zh) *	2018-12-12	2024-05-11	日商田邊三菱製藥股份有限公司	耐胃性控制釋放經口劑型
US12016851B2 (en) *	2022-04-11	2024-06-25	Chiesi Farmaceutici S.P.A.	Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4389393A (en) *	1982-03-26	1983-06-21	Forest Laboratories, Inc.	Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
FR2588188B1 (fr) *	1985-10-04	1988-01-08	Delalande Sa	Comprime de sel(s) hydrosoluble(s) de cinepazide a liberation programmee et son procede de preparation
US4786503A (en)	1987-04-06	1988-11-22	Alza Corporation	Dosage form comprising parallel lamine
US5387419A (en) *	1988-03-31	1995-02-07	The University Of Michigan	System for controlled release of antiarrhythmic agents
US5009895A (en) *	1990-02-02	1991-04-23	Merck & Co., Inc.	Sustained release with high and low viscosity HPMC
DE4139763A1 (de) *	1991-12-03	1993-06-09	Kali-Chemie Pharma Gmbh, 3000 Hannover, De	Kristalline fumarsaure salze von 9,9-alkylen-3,7-diazabicyclononan-verbindungen und diese verbindungen enthaltende arzneimittel
DE4329794C2 (de) *	1993-09-03	1997-09-18	Gruenenthal Gmbh	Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
CN1162263A (zh) *	1994-11-02	1997-10-15	詹森药业有限公司	西沙必利的缓释口服组合物
ZA959221B (en) *	1994-11-02	1997-04-30	Janssen Pharmaceutica Nv	Cisapride extended release
WO1997004752A1 (en) *	1995-07-26	1997-02-13	Duramed Pharmaceuticals, Inc.	Pharmaceutical compositions of conjugated estrogens and methods for their use
CA2216215A1 (en) *	1997-04-05	1998-10-05	Isa Odidi	Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
ATE302597T1 (de) *	1997-06-06	2005-09-15	Depomed Inc	Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US5948440A (en)	1997-12-17	1999-09-07	Ranbaxy Laboratories Limited	Modified release matrix formulation of cefaclor and cephalexin
US6099859A (en) *	1998-03-20	2000-08-08	Andrx Pharmaceuticals, Inc.	Controlled release oral tablet having a unitary core
WO1999064050A1 (en) *	1998-06-08	1999-12-16	Advanced Medicine, Inc.	Novel potassium channel drugs and their uses
AU764866B2 (en) *	1998-10-01	2003-09-04	Novartis Ag	New sustained release oral formulations
CO5140079A1 (es)	1998-10-14	2002-03-22	Novartis Ag	Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
JP2004518664A (ja)	2000-12-27	2004-06-24	ジェンザイム・コーポレーション	抗不整脈剤の調節された放出

2001
- 2001-09-28 DK DK01985673T patent/DK1345595T3/da active
- 2001-09-28 AT AT01985673T patent/ATE361060T1/de active
- 2001-09-28 SI SI200130732T patent/SI1345595T1/sl unknown
- 2001-09-28 WO PCT/EP2001/011285 patent/WO2002026214A1/en not_active Ceased
- 2001-09-28 KR KR1020037004552A patent/KR100833469B1/ko not_active Expired - Fee Related
- 2001-09-28 ES ES01985673T patent/ES2284709T3/es not_active Expired - Lifetime
- 2001-09-28 RU RU2003112459/15A patent/RU2285519C2/ru not_active IP Right Cessation
- 2001-09-28 PL PL360670A patent/PL203217B1/pl unknown
- 2001-09-28 SK SK355-2003A patent/SK287066B6/sk not_active IP Right Cessation
- 2001-09-28 IL IL15473101A patent/IL154731A0/xx active IP Right Grant
- 2001-09-28 EP EP01985673A patent/EP1345595B1/en not_active Expired - Lifetime
- 2001-09-28 BR BR0114272-0A patent/BR0114272A/pt not_active Application Discontinuation
- 2001-09-28 CA CA002426666A patent/CA2426666A1/en not_active Withdrawn
- 2001-09-28 NZ NZ524641A patent/NZ524641A/en not_active IP Right Cessation
- 2001-09-28 JP JP2002530044A patent/JP5049450B2/ja not_active Expired - Fee Related
- 2001-09-28 AU AU2002223572A patent/AU2002223572B2/en not_active Ceased
- 2001-09-28 PT PT01985673T patent/PT1345595E/pt unknown
- 2001-09-28 HU HU0301177A patent/HUP0301177A3/hu unknown
- 2001-09-28 CZ CZ20030898A patent/CZ299411B6/cs not_active IP Right Cessation
- 2001-09-28 AU AU2357202A patent/AU2357202A/xx active Pending
- 2001-09-28 MX MXPA03002769A patent/MXPA03002769A/es active IP Right Grant
- 2001-09-28 CN CN01816515XA patent/CN1466451B/zh not_active Expired - Fee Related
- 2001-09-28 DE DE60128263T patent/DE60128263T2/de not_active Expired - Lifetime
- 2001-09-28 DZ DZ013473A patent/DZ3473A1/fr active
- 2001-09-28 US US10/381,714 patent/US8034379B2/en not_active Expired - Fee Related
2003
- 2003-03-04 IL IL154731A patent/IL154731A/en not_active IP Right Cessation
- 2003-03-27 NO NO20031409A patent/NO20031409D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2002223572B2 (en)	2005-09-08
WO2002026214A1 (en)	2002-04-04
HUP0301177A3 (en)	2006-07-28
BR0114272A (pt)	2003-08-26
EP1345595A1 (en)	2003-09-24
SK287066B6 (sk)	2009-11-05
DE60128263D1 (de)	2007-06-14
IL154731A0 (en)	2003-10-31
CZ299411B6 (cs)	2008-07-16
KR100833469B1 (ko)	2008-05-29
HK1060691A1 (en)	2004-08-20
CZ2003898A3 (cs)	2003-06-18
PL360670A1 (en)	2004-09-20
AU2357202A (en)	2002-04-08
DK1345595T3 (da)	2007-09-10
DE60128263T2 (de)	2008-01-10
CN1466451B (zh)	2010-05-12
SK3552003A3 (en)	2003-10-07
KR20030036861A (ko)	2003-05-09
CA2426666A1 (en)	2002-04-04
ATE361060T1 (de)	2007-05-15
US20040013727A1 (en)	2004-01-22
MXPA03002769A (es)	2003-07-28
ES2284709T3 (es)	2007-11-16
DZ3473A1 (fr)	2002-04-04
IL154731A (en)	2008-11-26
JP2004509915A (ja)	2004-04-02
CN1466451A (zh)	2004-01-07
US8034379B2 (en)	2011-10-11
NZ524641A (en)	2004-09-24
PL203217B1 (pl)	2009-09-30
JP5049450B2 (ja)	2012-10-17
HUP0301177A2 (hu)	2003-10-28
EP1345595B1 (en)	2007-05-02
PT1345595E (pt)	2007-08-13
SI1345595T1 (sl)	2007-08-31
NO20031409D0 (no)	2003-03-27
RU2285519C2 (ru)	2006-10-20

Publication	Publication Date	Title
NO20031409D0 (no)	2003-03-27	Ionestyrkeuavhengig farmasöytiske preparat med langvarig frigivelse
AR045956A1 (es)	2005-11-16	Multiparticulas de pantoprazol y formulacion que las contiene
BR0107565A (pt)	2003-02-11	Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
CY1106072T1 (el)	2011-06-08	Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος
SE0300831D0 (sv)	2003-03-26	New formulations and use therof
ECSP045102A (es)	2004-06-28	Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
ATE302616T1 (de)	2005-09-15	Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
HUP0302114A2 (hu)	2003-10-28	Eritropoietin-fehérjét tartalmazó folyékony gyógyászati készítmény, eljárás előállítására és alkalmazása
BG108516A (en)	2004-12-30	Pharmaceutical formulation
ECSP083351A (es)	2008-08-29	Composiciones farmacéuticas
BR0314797A (pt)	2005-07-26	Derivados da pirimidineamida e o uso dos mesmos
DE60233898D1 (de)	2009-11-12	Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin-plasmaspiegeln
DE50005529D1 (de)	2004-04-08	Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60102590T2 (de)	2005-04-21	Darreichungsformen zur behandlung von oralen mykosen
NO20101070L (no)	2001-02-05	Fremgangsmate til dosering av et medikament, samt doseringsform
WO2001013898A3 (en)	2001-05-25	Pharmaceutical formulations with different release times
ATE464878T1 (de)	2010-05-15	Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
AU2001274374A1 (en)	2002-01-02	Matrix protein compositions for dentin regeneration
PT1343472E (pt)	2006-10-31	Pulverizacao nasal tixotropica
ATE226065T1 (de)	2002-11-15	Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
NO323466B1 (no)	2007-05-21	Nye kinolinyl-piperidin-4-yliden-metyl-benzamidderivater, fremgangsmate til fremstilling derav, anvendelse derav i medikamenter til behandling av smerte, samt farmasoytisk sammensetning som innbefatter slike derivater
HUP0002346A1 (hu)	2001-05-28	Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
SE0001916D0 (sv)	2000-05-23	Novel formulation
DE602004029993D1 (de)	2010-12-23	Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
NO20051159L (no)	2005-04-26	Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein

Legal Events

Date	Code	Title	Description
2013-02-11	FC2A	Withdrawal, rejection or dismissal of laid open patent application